|
1
|
Van Den Eeden SK, Tanner CM, Bernstein AL,
et al: Incidence of Parkinson’s disease: variation by age, gender,
and race/ethnicity. Am J Epidemiol. 157:1015–1022. 2003.
|
|
2
|
Elbaz A, Bower JH, Maraganore DM, et al:
Risk tables for parkinsonism and Parkinson’s disease. J Clin
Epidemiol. 55:25–31. 2002.
|
|
3
|
Dauer W and Przedborski S: Parkinson’s
disease: mechanisms and models. Neuron. 39:889–909. 2003.
|
|
4
|
Mylius V, Engau I, Teepker M, et al: Pain
sensitivity and descending inhibition of pain in Parkinson’s
disease. J Neurol Neurosurg Psychiatry. 80:24–28. 2009.
|
|
5
|
Grachev ID: Dopamine transporter imaging
with [123I]FP-CIT (DaTSCAN) in Parkinson’s disease with depressive
symptoms: a biological marker for causal relationships? J Neurol
Neurosurg Psychiatry. Jul 6–2013.(Epub ahead of print).
|
|
6
|
Blonder LX, Slevin JT, Kryscio RJ, et al:
Dopaminergic modulation of memory and affective processing in
Parkinson depression. Psychiatry Res. 210:146–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee JY, Kim JM, Ahn J, et al: Retinal
nerve fiber layer thickness and visual hallucinations in
Parkinson’s disease. Mov Disord. Jun 17–2013.(Epub ahead of print).
View Article : Google Scholar
|
|
8
|
Aarsland D, Zaccai J and Brayne C: A
systematic review of prevalence studies of dementia in Parkinson’s
disease. Mov Disord. 20:1255–1263. 2005.
|
|
9
|
Gan EC, Lau DP and Cheah KL: Stridor in
Parkinson’s disease: a case of ‘dry drowning’? J Laryngol Otol.
124:668–673. 2010.
|
|
10
|
Klebe S, Golmard JL, Nalls MA, et al: The
Val158Met COMT polymorphism is a modifier of the age at onset in
Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg
Psychiatry. 84:666–673. 2013.PubMed/NCBI
|
|
11
|
Rode J, Bentley A and Parkinson C:
Paraganglial cells of urinary bladder and prostate: potential
diagnostic problem. J Clin Pathol. 43:13–16. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Najafi MR, Chitsaz A, Askarian Z and
Najafi MA: Quality of sleep in patients with Parkinson’s disease.
Int J Prev Med. 4(Suppl 2): S229–S233. 2013.
|
|
13
|
Horvath J, Burkhard PR, Bouras C and
Kovari E: Etiologies of Parkinsonism in a century-long
autopsy-based cohort. Brain Pathol. 23:28–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olanow CW and Tatton WG: Etiology and
pathogenesis of Parkinson’s disease. Annu Rev Neurosci. 22:123–144.
1999.
|
|
15
|
Wirdefeldt K, Adami HO, Cole P, et al:
Epidemiology and etiology of Parkinson’s disease: a review of the
evidence. Eur J Epidemiol. 26(Suppl 1): S1–S58. 2011.
|
|
16
|
Vaglini F, Viaggi C, Piro V, et al:
Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav
Neurosci. 7:712013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lill CM, Roehr JT, McQueen MB, et al:
Comprehensive research synopsis and systematic meta-analyses in
Parkinson’s disease genetics: The PDGene database. PLoS Genet.
8:e10025482012.PubMed/NCBI
|
|
18
|
McInerney-Leo A, Hadley DW, Gwinn-Hardy K
and Hardy J: Genetic testing in Parkinson’s disease. Mov Disord.
20:1–10. 2005.
|
|
19
|
Bekris LM, Mata IF and Zabetian CP: The
genetics of Parkinson disease. J Geriatr Psychiatry Neurol.
23:228–242. 2010. View Article : Google Scholar
|
|
20
|
Jaber M, Robinson SW, Missale C and Caron
MG: Dopamine receptors and brain function. Neuropharmacology.
35:1503–1519. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Noble EP: D2 dopamine receptor gene in
psychiatric and neurologic disorders and its phenotypes. Am J Med
Genet B Neuropsychiatr Genet. 116B:103–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li MD, Ma JZ and Beuten J: Progress in
searching for susceptibility loci and genes for smoking-related
behaviour. Clin Genet. 66:382–392. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ritz B, Ascherio A, Checkoway H, et al:
Pooled analysis of tobacco use and risk of Parkinson disease. Arch
Neurol. 64:990–997. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Munafo M, Clark T, Johnstone E, et al: The
genetic basis for smoking behavior: a systematic review and
meta-analysis. Nicotine Tob Res. 6:583–597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oliveri RL, Annesi G, Zappia M, et al: The
dopamine D2 receptor gene is a susceptibility locus for Parkinson’s
disease. Mov Disord. 15:127–131. 2000.
|
|
26
|
Grevle L, Guzey C, Hadidi H, et al:
Allelic association between the DRD2 TaqI A polymorphism and
Parkinson’s disease. Mov Disord. 15:1070–1074. 2000.PubMed/NCBI
|
|
27
|
Costa-Mallen P, Costa LG, Smith-Weller T,
et al: Genetic polymorphism of dopamine D2 receptors in Parkinson’s
disease and interactions with cigarette smoking and MAO-B intron 13
polymorphism. J Neurol Neurosurg Psychiatry. 69:535–537. 2000.
|
|
28
|
Kelada SN, Costa-Mallen P, Costa LG, et
al: Gender difference in the interaction of smoking and monoamine
oxidase B intron 13 genotype in Parkinson’s disease.
Neurotoxicology. 23:515–519. 2002.PubMed/NCBI
|
|
29
|
Tan EK, Tan Y, Chai A, et al: Dopamine D2
receptor TaqIA and TaqIB polymorphisms in Parkinson’s disease. Mov
Disord. 18:593–595. 2003.
|
|
30
|
Chen X: The association between cigarette
smoking and genes and Parkinson’s disease. Capital Med Univ; 2006,
(In Chinese).
|
|
31
|
Singh M, Khan AJ, Shah PP, et al:
Polymorphism in environment responsive genes and association with
Parkinson disease. Mol Cell Biochem. 312:131–138. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W: Correlation study between dopamine
D2 receptor gene TaqI polymorphism and Parkinson’s disease. J Clin
Psyc Med. 21:3192009.PubMed/NCBI
|
|
33
|
Lee JY, Lee EK, Park SS, et al:
Association of DRD3 and GRIN2B with impulse control and related
behaviors in Parkinson’s disease. Mov Disord. 24:1803–1810.
2009.PubMed/NCBI
|
|
34
|
Kiyohara C, Miyake Y, Koyanagi M, et al:
Genetic polymorphisms involved in dopaminergic neurotransmission
and risk for Parkinson’s disease in a Japanese population. BMC
Neurol. 11:892011.
|
|
35
|
Lee JY, Cho J, Lee EK, et al: Differential
genetic susceptibility in diphasic and peak-dose dyskinesias in
Parkinson’s disease. Mov Disord. 26:73–79. 2011.PubMed/NCBI
|
|
36
|
McGuire V, Van Den Eeden SK, Tanner CM, et
al: Association of DRD2 and DRD3 polymorphisms with Parkinson’s
disease in a multiethnic consortium. J Neurol Sci. 307:22–29.
2011.
|
|
37
|
Nanko S, Hattori M, Ueki A and Ikeda K:
Dopamine D3 and D4 receptor gene polymorphisms and Parkinson’s
disease. Lancet. 342:2501993.
|
|
38
|
Nanko S, Ueki A, Hattori M, et al: No
allelic association between Parkinson’s disease and dopamine D2,
D3, and D4 receptor gene polymorphisms. Am J Med Genet. 54:361–364.
1994.
|
|
39
|
Higuchi S, Muramatsu T, Arai H, et al:
Polymorphisms of dopamine receptor and transporter genes and
Parkinson’s disease. J Neural Transm Park Dis Dement Sect.
10:107–113. 1995.
|
|
40
|
Wang J, Liu ZL and Chen B: Polymorphisms
of dopamine D3 receptor gene and Parkinson’s disease. Chin J New
Drugs and Clin Remedy. 19:108–109. 2000.
|
|
41
|
Button KS, Ioannidis JP, Mokrysz C, et al:
Power failure: why small sample size undermines the reliability of
neuroscience. Nat Rev Neurosci. 14:365–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu WD, Zhou M, Peng H, et al: Lack of
association of IL-6 polymorphism with rheumatoid arthritis/type 1
diabetes: A meta-analysis. Joint Bone Spine. 80:477–481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tao JH, Zou YF, Feng XL, et al:
Meta-analysis of TYK2 gene polymorphisms association with
susceptibility to autoimmune and inflammatory diseases. Mol Biol
Rep. 38:4663–4672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Excoffier L, Laval G and Schneider S:
Arlequin (version 3.0): an integrated software package for
population genetics data analysis. Evol Bioinform Online. 1:47–50.
2005.PubMed/NCBI
|
|
45
|
Coory MD: Comment on: Heterogeneity in
meta-analysis should be expected and appropriately quantified. Int
J Epidemiol. 39:932–933. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kawalec P, Mikrut A, Wisniewska N and Pilc
A: The effectiveness of tofacitinib, a novel Janus kinase
inhibitor, in the treatment of rheumatoid arthritis: a systematic
review and meta-analysis. Clin Rheumatol. 32:1415–1424. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gibson E, Fenster A and Ward AD: The
impact of registration accuracy on imaging validation study design:
A novel statistical power calculation. Med Image Anal. 17:805–815.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Thompson J, Thomas N, Singleton A, et al:
D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced
dopamine D2 receptor binding in the human striatum associated with
the A1 allele. Pharmacogenetics. 7:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Noble EP: The D2 dopamine receptor gene: a
review of association studies in alcoholism and phenotypes.
Alcohol. 16:33–45. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Talkowski ME, Mansour H, Chowdari KV, et
al: Novel, replicated associations between dopamine D3 receptor
gene polymorphisms and schizophrenia in two independent samples.
Biol Psychiatry. 60:570–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
